{"id":2338,"date":"2020-07-08T00:00:00","date_gmt":"2020-07-08T00:00:00","guid":{"rendered":"http:\/\/centogene.vl22350.dinaserver.com\/2338"},"modified":"2020-07-08T00:00:00","modified_gmt":"2020-07-08T00:00:00","slug":"centogene-anuncia-propuesta-de-oferta-publica-primaria-y-secundaria-de-acciones-ordinarias","status":"publish","type":"post","link":"https:\/\/www.centogene.com\/es\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/","title":{"rendered":"CENTOGENE anuncia propuesta de oferta p\u00fablica primaria y secundaria de acciones ordinarias"},"content":{"rendered":"<p>CAMBRIDGE, Massachusetts, ROSTOCK, Alemania y BERL\u00cdN, 7 de julio de 2020 (Globe Newswire) \u2013 Centogene NV (Nasdaq: CNTG), empresa en fase comercial especializada en enfermedades raras que transforma datos cl\u00ednicos y gen\u00e9ticos del mundo real en informaci\u00f3n \u00fatil para pacientes, m\u00e9dicos y compa\u00f1\u00edas farmac\u00e9uticas, anunci\u00f3 hoy que, junto con algunos accionistas vendedores, ha iniciado una oferta p\u00fablica de suscripci\u00f3n de 3.500.000 acciones ordinarias de la Compa\u00f1\u00eda, compuesta por 2.000.000 de acciones ordinarias ofrecidas por la Compa\u00f1\u00eda y 1.500.000 de acciones ordinarias ofrecidas por los accionistas vendedores. Adem\u00e1s, los accionistas vendedores prev\u00e9n otorgar a los suscriptores una opci\u00f3n de 30 d\u00edas para comprar hasta 525.000 acciones ordinarias adicionales al precio de la oferta p\u00fablica, menos los descuentos y comisiones de suscripci\u00f3n. La oferta est\u00e1 sujeta a condiciones del mercado y otras condiciones, y no puede haber garant\u00eda de si la oferta podr\u00e1 completarse o no, ni de cu\u00e1ndo, ni de su tama\u00f1o real o de sus t\u00e9rminos.<\/p>\n<p>Credit Suisse y SVB Leerink act\u00faan como gestores conjuntos de la oferta propuesta, mientras que Baird, BTIG y Kempen &amp; Co act\u00faan como cogestores.<\/p>\n<p>CENTOGENE pretende utilizar los ingresos netos de la oferta en investigaci\u00f3n y desarrollo para apoyar el desarrollo de medicamentos hu\u00e9rfanos con su plataforma de informaci\u00f3n basada en el conocimiento, as\u00ed como para capital de trabajo y otros fines corporativos generales. Una parte de los ingresos netos tambi\u00e9n podr\u00e1 utilizarse para adquirir o invertir en negocios, activos o tecnolog\u00edas complementarios.<\/p>\n<p>La oferta se realiza \u00fanicamente mediante un prospecto. Se pueden obtener copias del prospecto preliminar de la oferta, cuando est\u00e9n disponibles, de forma gratuita, visitando EDGAR en el sitio web de la Comisi\u00f3n de Bolsa y Valores (SEC): www.sec.gov. Alternativamente, se pueden obtener copias del prospecto preliminar, cuando est\u00e9n disponibles, de Credit Suisse Securities (USA) LLC, Atenci\u00f3n: Departamento de Prospectos, 6933 Louis Stephens Drive, Morrisville, NC 27560, por tel\u00e9fono al (800) 221-1037 o por correo electr\u00f3nico a usa.prospectus@credit-suisse.com; o de SVB Leerink LLC, Atenci\u00f3n: Departamento de Sindicatos, One Federal Street, Piso 37, Boston, MA 02110, por tel\u00e9fono al (800) 808-7525, ext. 6218 o por correo electr\u00f3nico a sindicato@svbleerink.com .<\/p>\n<p>Se ha presentado ante la SEC una declaraci\u00f3n de registro relativa a la oferta, pero a\u00fan no ha entrado en vigor. Los valores no podr\u00e1n venderse ni aceptarse ofertas de compra antes de que entre en vigor la declaraci\u00f3n de registro.<\/p>\n<p>Este comunicado de prensa no constituir\u00e1 una oferta de venta ni una solicitud de oferta de compra de estos valores, ni habr\u00e1 ninguna venta de estos valores en ning\u00fan estado o jurisdicci\u00f3n en el que dicha oferta, solicitud o venta sea ilegal antes del registro o calificaci\u00f3n seg\u00fan las leyes de valores de dicho estado o jurisdicci\u00f3n.<\/p>\n<h2 class=\"h3\">Acerca de CENTOGENE<strong> <\/strong><\/h2>\n<p>CENTOGENE se dedica al diagn\u00f3stico y la investigaci\u00f3n de enfermedades raras, transformando datos cl\u00ednicos y gen\u00e9ticos del mundo real en informaci\u00f3n pr\u00e1ctica para pacientes, m\u00e9dicos y compa\u00f1\u00edas farmac\u00e9uticas. Nuestro objetivo es racionalizar las decisiones terap\u00e9uticas y acelerar el desarrollo de nuevos medicamentos hu\u00e9rfanos mediante nuestro amplio conocimiento sobre enfermedades raras, que incluye datos epidemiol\u00f3gicos y cl\u00ednicos, as\u00ed como biomarcadores innovadores. CENTOGENE ha desarrollado una plataforma global propia para enfermedades raras basada en nuestro repositorio de datos del mundo real, con aproximadamente 3.000 millones de puntos de datos ponderados de m\u00e1s de 530.000 pacientes de m\u00e1s de 120 pa\u00edses diferentes, al 31 de marzo de 2020.<\/p>\n<p>La plataforma de la Compa\u00f1\u00eda incluye datos epidemiol\u00f3gicos, fenot\u00edpicos y gen\u00e9ticos que reflejan una poblaci\u00f3n global, as\u00ed como un biobanco de muestras de sangre de estos pacientes. CENTOGENE considera que esta es la \u00fanica plataforma que analiza exhaustivamente datos multinivel para mejorar la comprensi\u00f3n de las enfermedades hereditarias raras, lo que puede facilitar la identificaci\u00f3n de pacientes y mejorar la capacidad de nuestros socios farmac\u00e9uticos para comercializar medicamentos hu\u00e9rfanos. Al 31 de marzo de 2020, la Compa\u00f1\u00eda colaboraba con 39 socios farmac\u00e9uticos que abarcaban m\u00e1s de 45 enfermedades raras diferentes.<\/p>\n<h5>Contacto con los medios<strong> <\/strong><\/h5>\n<p>CENTOGENE<br \/> Sun Kim<br \/> Director de Estrategia y Relaciones con Inversores<br \/> <a href=\"mailto:investor.relations@centogene.com\" title=\"Escribe un correo electr\u00f3nico\">investor.relations@centogene.com<\/a><\/p>\n<p>Consultor\u00eda FTI<br \/> Bridie Lawlor<br \/> +1.917.929.5684<br \/> <a href=\"mailto:bridie.lawlor@fticonsulting.com\" title=\"Escribe un correo electr\u00f3nico\">bridie.lawlor@fticonsulting.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 07, 2020 (Globe Newswire) &#8211; Centogene N.V. (Nasdaq: CNTG), a commercial-stage company [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2338","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares | CENTOGENE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.centogene.com\/es\/centogene-anuncia-propuesta-de-oferta-publica-primaria-y-secundaria-de-acciones-ordinarias\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares | CENTOGENE\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 07, 2020 (Globe Newswire) &#8211; Centogene N.V. (Nasdaq: CNTG), a commercial-stage company [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.centogene.com\/es\/centogene-anuncia-propuesta-de-oferta-publica-primaria-y-secundaria-de-acciones-ordinarias\/\" \/>\n<meta property=\"og:site_name\" content=\"CENTOGENE\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-08T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"740\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"admincg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"admincg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/\"},\"author\":{\"name\":\"admincg\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\"},\"headline\":\"CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares\",\"datePublished\":\"2020-07-08T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/\"},\"wordCount\":643,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/\",\"name\":\"CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares | CENTOGENE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\"},\"datePublished\":\"2020-07-08T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.centogene.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"name\":\"CENTOGENE\",\"description\":\"Guiding Precision Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.centogene.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\",\"name\":\"CENTOGENE\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"contentUrl\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"width\":246,\"height\":246,\"caption\":\"CENTOGENE\"},\"image\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/centogene\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UClZxtN_laC1_ZtCdxkasdPQ\",\"https:\\\/\\\/www.instagram.com\\\/_centogene_\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\",\"name\":\"admincg\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/es\\\/author\\\/admincg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CENTOGENE Anuncia Propuesta de Oferta P\u00fablica Primaria y Secundaria de Acciones Ordinarias | CENTOGENE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.centogene.com\/es\/centogene-anuncia-propuesta-de-oferta-publica-primaria-y-secundaria-de-acciones-ordinarias\/","og_locale":"es_ES","og_type":"article","og_title":"CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares | CENTOGENE","og_description":"CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 07, 2020 (Globe Newswire) &#8211; Centogene N.V. (Nasdaq: CNTG), a commercial-stage company [&hellip;]","og_url":"https:\/\/www.centogene.com\/es\/centogene-anuncia-propuesta-de-oferta-publica-primaria-y-secundaria-de-acciones-ordinarias\/","og_site_name":"CENTOGENE","article_published_time":"2020-07-08T00:00:00+00:00","og_image":[{"width":740,"height":416,"url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp","type":"image\/webp"}],"author":"admincg","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"admincg","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/#article","isPartOf":{"@id":"https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/"},"author":{"name":"admincg","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b"},"headline":"CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares","datePublished":"2020-07-08T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/"},"wordCount":643,"commentCount":0,"publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/","url":"https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/","name":"CENTOGENE Anuncia Propuesta de Oferta P\u00fablica Primaria y Secundaria de Acciones Ordinarias | CENTOGENE","isPartOf":{"@id":"https:\/\/www.centogene.com\/#website"},"datePublished":"2020-07-08T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.centogene.com\/centogene-announces-proposed-primary-and-secondary-public-offering-of-common-shares\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.centogene.com\/"},{"@type":"ListItem","position":2,"name":"CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares"}]},{"@type":"WebSite","@id":"https:\/\/www.centogene.com\/#website","url":"https:\/\/www.centogene.com\/","name":"CENTOGENE","description":"Impulsar la medicina de precisi\u00f3n","publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.centogene.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.centogene.com\/#organization","name":"CENTOGENE","url":"https:\/\/www.centogene.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","contentUrl":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","width":246,"height":246,"caption":"CENTOGENE"},"image":{"@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/centogene","https:\/\/www.youtube.com\/channel\/UClZxtN_laC1_ZtCdxkasdPQ","https:\/\/www.instagram.com\/_centogene_\/"]},{"@type":"Person","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b","name":"administrador","url":"https:\/\/www.centogene.com\/es\/author\/admincg\/"}]}},"_links":{"self":[{"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/posts\/2338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/comments?post=2338"}],"version-history":[{"count":0,"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/posts\/2338\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/media?parent=2338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/categories?post=2338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/tags?post=2338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}